Literature DB >> 21848575

When to publish measures of disproportionality derived from spontaneous reporting databases?

Anthonius de Boer1.   

Abstract

Mesh：

Year:  2011        PMID： 21848575      PMCID： PMC3244637          DOI： 10.1111/j.1365-2125.2011.04087.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  10 in total

1.  Detecting drug-drug interactions using a database for spontaneous adverse drug reactions: an example with diuretics and non-steroidal anti-inflammatory drugs.

Authors:  E P van Puijenbroek; A C Egberts; E R Heerdink; H G Leufkens
Journal:  Eur J Clin Pharmacol       Date:  2000-12       Impact factor: 2.953

2.  Serum sickness-like reactions to cefaclor.

Authors:  B H Stricker; J G Tijssen
Journal:  J Clin Epidemiol       Date:  1992-10       Impact factor: 6.437

3.  A potential competition bias in the detection of safety signals from spontaneous reporting databases.

Authors:  Antoine Pariente; Marie Didailler; Paul Avillach; Ghada Miremont-Salamé; Annie Fourrier-Reglat; Françoise Haramburu; Nicholas Moore
Journal:  Pharmacoepidemiol Drug Saf       Date:  2010-11       Impact factor: 2.890

4.  Selected control events and reporting odds ratio in signal detection methodology.

Authors:  Nobuhiro Ooba; Kiyoshi Kubota
Journal:  Pharmacoepidemiol Drug Saf       Date:  2010-11       Impact factor: 2.890

5.  The history of disproportionality measures (reporting odds ratio, proportional reporting rates) in spontaneous reporting of adverse drug reactions.

Authors:  Nicholas Moore; Frantz Thiessard; Bernard Begaud
Journal:  Pharmacoepidemiol Drug Saf       Date:  2005-04       Impact factor: 2.890

Review 6.  Quantitative signal detection using spontaneous ADR reporting.

Authors:  A Bate; S J W Evans
Journal:  Pharmacoepidemiol Drug Saf       Date:  2009-06       Impact factor: 2.890

7.  Non-puerperal lactation associated with antidepressant drug use.

Authors:  A C Egberts; R H Meyboom; F H De Koning; A Bakker; H G Leufkens
Journal:  Br J Clin Pharmacol       Date:  1997-09       Impact factor: 4.335

8.  Memory disorders associated with consumption of drugs: updating through a case/noncase study in the French PharmacoVigilance Database.

Authors:  Francois Chavant; Sylvie Favrelière; Claire Lafay-Chebassier; Caroline Plazanet; Marie-Christine Pérault-Pochat
Journal:  Br J Clin Pharmacol       Date:  2011-12       Impact factor: 4.335

9.  Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death.

Authors:  M L De Bruin; M Pettersson; R H B Meyboom; A W Hoes; H G M Leufkens
Journal:  Eur Heart J       Date:  2005-01-06       Impact factor: 29.983

10.  Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias.

Authors:  Antoine Pariente; Fleur Gregoire; Annie Fourrier-Reglat; Françoise Haramburu; Nicholas Moore
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606
  10 in total
  11 in total

1.  Two cheers or three for treatment guidelines? Nudging prescribers in right directions.

Authors:  Yoon K Loke; James M Ritter
Journal:  Br J Clin Pharmacol       Date:  2011-12       Impact factor: 4.335

Review 2.  Can Disproportionality Analysis of Post-marketing Case Reports be Used for Comparison of Drug Safety Profiles?

Authors:  Christiane Michel; Emil Scosyrev; Michael Petrin; Robert Schmouder
Journal:  Clin Drug Investig       Date:  2017-05       Impact factor: 2.859

3.  Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system.

Authors:  Emanuel Raschi; Elisabetta Poluzzi; Ariola Koci; Francesco Salvo; Antoine Pariente; Maurizio Biselli; Ugo Moretti; Nicholas Moore; Fabrizio De Ponti
Journal:  Br J Clin Pharmacol       Date:  2015-05-20       Impact factor: 4.335

4.  Psychiatric Disorders and Montelukast in Children: A Disproportionality Analysis of the VigiBase(®).

Authors:  Ana Aldea Perona; Mar García-Sáiz; Emilio Sanz Álvarez
Journal:  Drug Saf       Date:  2016-01       Impact factor: 5.606

5.  Gabapentin drug misuse signals: A pharmacovigilance assessment using the FDA adverse event reporting system.

Authors:  Rachel Vickers-Smith; Jiangwen Sun; Richard J Charnigo; Michelle R Lofwall; Sharon L Walsh; Jennifer R Havens
Journal:  Drug Alcohol Depend       Date:  2019-11-02       Impact factor: 4.492

6.  Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis.

Authors:  Richard M Turner; Chun S Kwok; Chen Chen-Turner; Chinedu A Maduakor; Sonal Singh; Yoon K Loke
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

Review 7.  Sources of Safety Data and Statistical Strategies for Design and Analysis: Postmarket Surveillance.

Authors:  Rima Izem; Matilde Sanchez-Kam; Haijun Ma; Richard Zink; Yueqin Zhao
Journal:  Ther Innov Regul Sci       Date:  2018-01-08       Impact factor: 1.778

Review 8.  Data mining of the public version of the FDA Adverse Event Reporting System.

Authors:  Toshiyuki Sakaeda; Akiko Tamon; Kaori Kadoyama; Yasushi Okuno
Journal:  Int J Med Sci       Date:  2013-04-25       Impact factor: 3.738

9.  Adverse event profiles of solvent-based and nanoparticle albumin-bound paclitaxel formulations using the Food and Drug Administration Adverse Event Reporting System.

Authors:  Misa Naganuma; Kohei Tahara; Shiori Hasegawa; Akiho Fukuda; Sayaka Sasaoka; Haruna Hatahira; Yumi Motooka; Satoshi Nakao; Ririka Mukai; Kouseki Hirade; Tomoaki Yoshimura; Takeshi Kato; Hirofumi Takeuchi; Mitsuhiro Nakamura
Journal:  SAGE Open Med       Date:  2019-03-11

10.  Computing limits on medicine risks based on collections of individual case reports.

Authors:  Ola Caster; G Niklas Norén; I Ralph Edwards
Journal:  Theor Biol Med Model       Date:  2014-03-24       Impact factor: 2.432
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.